Neomorph, Inc
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma (NCT07300241) | Neomorph, Inc | 2025-12-19 |
Track Neomorph, Inc automatically
Every clearance here is in the API, with alerts when new ones post.